The Global Dupuytren's Disease Market is Expected to Grow at Considerable Rate Owing to Increasing Prescription Volumes of Branded Drugs
Global Dupuytrens Disease Market Trends |
The global Dupuytren's disease market relies majorly on surgical interventions and drugs for treatment. Dupuytren's disease is a medical condition characterized by formation of fibrous cords and nodules under the skin of the palm, which causes fingers to bend towards the palm permanently over the time. Non-surgical treatments such as needle aponeurotomy and collagenase injections are preferred line of treatments owing to their less invasiveness.
The global Dupuytren's disease market is estimated to be
valued at US$ 4.3 Bn in 2024 and is
expected to exhibit a CAGR of 4.6%
over the forecast period from 2024 to 2031.
The Global
Dupuytrens Disease Market Trends can be attributed rising prescription
volumes of branded drugs for disease management. Development of recombinant and
biosimilar drugs can lead to new treatment opportunities that favor market
growth. Key players like Endo International Plc, Bristol-Meyers Squibb Company,
and Spear Pharmaceuticals offer drugs for disease treatment that drive overall
prescription volumes. Global expansion of key companies to emerging regions
will boost the regional market size over the forecast period.
Key Takeaways
Key players operating in the global Dupuytren's disease
market are Endo International Plc, Bristol-Meyers Squibb Company, Spear
Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma
A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua
Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd., 180 Life
Sciences Corp.
Key opportunities in the market include development of novel therapeutics such
as recombinant collagenase injections and biosimilars. This along with clinical
trials for pipeline drugs will help expand the treatment landscape for disease
management.
Globally, companies are expanding their operations in high growth markets such
as Asia Pacific and Latin America through partnerships and acquisitions. This
allows them to tap unmet needs and boost sales volumes in emerging countries.
Market Drivers
Rising prescription volumes of branded drugs for disease
management is a key driver. Developed markets see higher prescription rates for
branded drugs compared to generics. This positively impacts the revenue growth
of key players.
Market Restraints
Expiry of patents of blockbuster drugs reduces profit
margins of companies. Additionally, pricing pressure due to market entry of
biosimilars poses a major challenge. Stringent regulations for drug approvals
further delay market entry of novel therapies.
Segment Analysis
The Global Dupuytren's Disease Market is dominated by the diagnostics segment
which is expected to possess a market share of 44.3% in 2024. This is due to
the growing number of patients opting for radiographic testing such as x-ray or
MRI for early diagnosis of the disease. Within diagnostics, imaging testing
sub-segment holds the largest market share owing to advantages such as
non-invasive nature and ability to detect the disease at earlier stages.
The treatment segment is further categorized into drug therapy, surgery, and
other therapies. The surgery sub-segment presently dominates the overall
treatment segment attributed to increasing preference of patients and
physicians for surgical intervention to correct finger contractures caused by
Dupuytren's disease.
Global Analysis
Regionally, North America held the largest share of the global Dupuytren's
disease market in 2024 and is expected to grow at a CAGR of 4.0% during the
forecast period. Factors such as advanced healthcare infrastructure, rising
patient awareness about the disease, and new product launches by key players
drive the market growth. On the other hand, Asia Pacific is projected to
experience the fastest growth rate over the forecast years owing to increasing
per capita healthcare expenditure and growing medical tourism in countries like
India and China.
Europe captured the second largest market share in 2024 and is likely to
maintain its position through 2031. Key growth determinants in the region
include well-established reimbursement policies and continual research for
enhanced treatment options.
Get
More Insights On- Global
Dupuytrens Disease Market
Comments
Post a Comment